Swiss pharmaceutical and diagnostics giant Roche announced the success of a pivotal clinical trial for its drug divarasib in the treatment of a form of lung cancer.

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer